News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
728,935 Results
Type
Article (43183)
Company Profile (463)
Press Release (685276)
Multimedia
Podcasts (106)
Webinars (20)
Section
Business (209111)
Career Advice (2032)
Deals (36083)
Drug Delivery (108)
Drug Development (83812)
Employer Resources (174)
FDA (16588)
Job Trends (15163)
News (353662)
Policy (33237)
Tag
Academia (2648)
Accelerated approval (18)
Adcomms (28)
Allergies (118)
Alliances (51110)
ALS (141)
Alzheimer's disease (1609)
Antibody-drug conjugate (ADC) (234)
Approvals (16661)
Artificial intelligence (416)
Autoimmune disease (72)
Automation (27)
Bankruptcy (373)
Best Places to Work (11840)
BIOSECURE Act (20)
Biosimilars (150)
Biotechnology (331)
Bladder cancer (133)
Brain cancer (48)
Breast cancer (494)
Cancer (3865)
Cardiovascular disease (314)
Career advice (1712)
Career pathing (34)
CAR-T (232)
CDC (44)
Cell therapy (628)
Cervical cancer (31)
Clinical research (69936)
Collaboration (1351)
Company closure (4)
Compensation (928)
Complete response letters (51)
COVID-19 (2738)
CRISPR (78)
C-suite (580)
Cystic fibrosis (136)
Data (4539)
Decentralized trials (2)
Denatured (34)
Depression (104)
Diabetes (421)
Diagnostics (6593)
Digital health (34)
Diversity (10)
Diversity, equity & inclusion (45)
Drug discovery (196)
Drug pricing (164)
Drug shortages (29)
Duchenne muscular dystrophy (202)
Earnings (90031)
Editorial (49)
Employer branding (21)
Employer resources (152)
Events (118929)
Executive appointments (954)
FDA (19010)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (6)
Frontotemporal dementia (15)
Funding (1222)
Gene editing (167)
Generative AI (31)
Gene therapy (513)
GLP-1 (904)
Government (4694)
Grass and pollen (5)
Guidances (348)
Healthcare (19188)
HIV (44)
Huntington's disease (36)
IgA nephropathy (63)
Immunology and inflammation (221)
Immuno-oncology (18)
Indications (53)
Infectious disease (2963)
Inflammatory bowel disease (178)
Inflation Reduction Act (16)
Influenza (94)
Intellectual property (188)
Interviews (315)
IPO (16896)
IRA (51)
Job creations (3710)
Job search strategy (1438)
Kidney cancer (15)
Labor market (72)
Layoffs (566)
Leadership (29)
Legal (8014)
Liver cancer (87)
Longevity (11)
Lung cancer (559)
Lymphoma (264)
Machine learning (30)
Management (59)
Manufacturing (591)
MASH (135)
Medical device (13758)
Medtech (13781)
Mergers & acquisitions (20058)
Metabolic disorders (1066)
Multiple sclerosis (133)
NASH (19)
Neurodegenerative disease (213)
Neuropsychiatric disorders (57)
Neuroscience (2605)
NextGen: Class of 2025 (6758)
Non-profit (4563)
Now hiring (58)
Obesity (509)
Opinion (260)
Ovarian cancer (134)
Pain (155)
Pancreatic cancer (168)
Parkinson's disease (235)
Partnered (27)
Patents (404)
Patient recruitment (315)
Peanut (53)
People (59640)
Pharmaceutical (86)
Pharmacy benefit managers (24)
Phase I (21961)
Phase II (30852)
Phase III (22808)
Pipeline (2704)
Policy (255)
Postmarket research (2602)
Preclinical (9424)
Press Release (67)
Prostate cancer (196)
Psychedelics (50)
Radiopharmaceuticals (275)
Rare diseases (638)
Real estate (6045)
Recruiting (70)
Regulatory (23946)
Reports (51)
Research institute (2446)
Resumes & cover letters (353)
Rett syndrome (15)
RNA editing (15)
RSV (66)
Schizophrenia (131)
Series A (205)
Series B (156)
Service/supplier (11)
Sickle cell disease (80)
Special edition (24)
Spinal muscular atrophy (154)
Sponsored (35)
Startups (3789)
State (2)
Stomach cancer (15)
Supply chain (93)
Tariffs (80)
The Weekly (70)
Vaccines (928)
Venture capital (65)
Weight loss (335)
Women's health (56)
Worklife (18)
Date
Today (1)
Last 7 days (712)
Last 30 days (2455)
Last 365 days (31292)
2025 (25215)
2024 (36300)
2023 (41015)
2022 (52278)
2021 (56764)
2020 (54920)
2019 (47416)
2018 (35697)
2017 (33023)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (744)
Alabama (77)
Alaska (7)
Arizona (275)
Arkansas (14)
Asia (40102)
Australia (6662)
California (9333)
Canada (2837)
China (868)
Colorado (392)
Connecticut (411)
Delaware (257)
Europe (87880)
Florida (1373)
Georgia (300)
Hawaii (2)
Idaho (60)
Illinois (731)
India (45)
Indiana (440)
Iowa (20)
Japan (319)
Kansas (121)
Kentucky (35)
Louisiana (18)
Maine (68)
Maryland (1225)
Massachusetts (6926)
Michigan (282)
Minnesota (537)
Mississippi (4)
Missouri (110)
Montana (31)
Nebraska (25)
Nevada (103)
New Hampshire (76)
New Jersey (2568)
New Mexico (30)
New York (2521)
North Carolina (1322)
North Dakota (9)
Northern California (4297)
Ohio (281)
Oklahoma (20)
Oregon (40)
Pennsylvania (1950)
Puerto Rico (18)
Rhode Island (44)
South America (1113)
South Carolina (48)
South Dakota (1)
Southern California (3580)
Tennessee (146)
Texas (1437)
United States (33970)
Utah (273)
Virginia (226)
Washington D.C. (78)
Washington State (791)
West Virginia (4)
Wisconsin (82)
Wyoming (1)
728,935 Results for "denali therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce Approval from Denali’s Shareholders of the Previously Announced Business Combination
September 5, 2025
·
8 min read
Press Releases
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)
October 14, 2025
·
6 min read
Press Releases
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
August 12, 2025
·
12 min read
Press Releases
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce the Closing of Their Previously Announced Business Combination
September 23, 2025
·
9 min read
Press Releases
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announced the Closing of Their Previously Announced Business Combination on September 22, 2025
September 23, 2025
·
8 min read
ALS
Denali Suffers Another ALS Fail With Phase II/III Flop
Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and Amylyx have seen similarly disappointing results.
January 7, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex
August 13, 2025
·
12 min read
Press Releases
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
July 8, 2025
·
8 min read
Press Releases
Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome
May 7, 2025
·
12 min read
ALS
HEALEY ALS Trial Serves Up More Disappointment as Denali, AbbVie/Calico Fail
Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the latest setbacks for the controversial platform trial, the results from which have largely mirrored the dismal success rate in ALS overall.
January 10, 2025
·
5 min read
·
Heather McKenzie
1 of 72,894
Next
